Italia markets open in 8 hours 44 minutes

Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0861
-0,0011(-0,10%)
Bitcoin EUR
64.207,34
+3.106,45(+5,08%)
CMC Crypto 200
1.467,01
+112,60(+8,31%)

NBIX May 2024 105.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,4000

0,0000

(0,00%)

In data: 10:44AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat